FDA Acknowledges Pain Reduction Data Supporting Rexlemestrocel-L Efficacy
The US Food and Drug Administration (FDA) has acknowledged clinical data showing that Rexlemestrocel-L reduced pain intensity over 12 months, supporting the product’s efficacy in treating back pain. The agency also indicated that the approval label may include language related to opioid reduction.
Clinical Data | 19/01/2026 | By News Bureau
Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek 2025
Sun Pharma presented new clinical data on its investigational GLP-1 agonist, Utreglutide, at ObesityWeek 2025, highlighting meaningful reductions in body weight, waist circumference, and lipid parameters across two studies, with the therapy showing a favourable and class-consistent safety profile.
Clinical Data | 14/11/2025 | By Dineshwori | 206
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy